.png)
Dr. Huizinga has led teams of highly qualified research leaders internationally and has taught them how to find the attitude that allows their team to perform at the highest level. He has lectured and led leadership classes internationally, and at the local level.
Dr. Huizinga has a PhD (Organizational Leadership) from Regent University. He has published in leadership journals and is the editor of two texts on leadership. In your sessions, you will learn how to find the attitude that transforms your business, transforms your team and transforms your world.
Dr. Robert Huizinga has more than 25 years of drug development expertise. He as seen the development of voclosporin (Lupkynis®) since its inception, led the Phase I-III global clinical program of Lupkynis® through 2013, and continued to work with the Clinical Development team through the approval of Lupkynis® in the US and numerous EU agencies. That gave him a unique insight into drug development from pre-clinical to approval. Rob co founded Aurinia Pharmaceuticals Inc., and most recently Rob led the Aurinia Research group helping them understand the translational impact of calcineurin inhibition beyond immunosuppression. In addition he was responsible for the preclinical development of new compounds in autoimmune disease. He has participated with SONG, KHI, and the Controversies Conference on Glomerular Diseases with KDIGO. Before joining the industry, Rob was a Clinical Investigator and Medical Epidemiologist at the University of Alberta Division of Nephrology & Immunology, where he was involved in more than 60 clinical trials from Phase I through Phase IV and the successful development of numerous compounds including CellCept®, Neoral®, Prograf®, Aranesp® and Simulect®. He has numerous publications in leadership, immunology, transplantation and autoimmune disease.
From molecule inception to Regulatory approvals, from being an Investigator to being a Sponsor, we have the expertise and tools needed to help your program.
Dr. Huizinga has raised over $500 million USD on the public markets. That takes knowing who to approach, what their needs are and when to raise the funds.
Without the ability to lead a team successfully, skills are not enough. We have led multi-disciplinary teams across multiple programs allowing the company to be successful in moving new medications forward.
